BNP and its N-terminal non-active prohormone (NT-proBNP), which is more stable and has a longer half-life, are widely used in common clinical practice for the diagnosis and management of heart failure (HF) and for the prognostic stratification of patients with a high CV risk [12]. The gene discussed is NPPB; the disease is heart failure.